MTAP and renal cell carcinoma: In general, these results demonstrated that although MTAP/CDKN2AMUT RCC may be insensitive to targeted therapy, the high degree of tumor heterogeneity and immune-excluded TME reflected that MTAP/CDKN2AMUT patients could benefit from immunotherapies.